CSCO Guidelines for Colorectal Cancer Version 2024: Updates and Discussions

Overview

Journal Chin J Cancer Res

Specialty Oncology

Date 2024 Jul 11

PMID 38988483

Authors

Liubo Chen

Hanguang Hu

Ying Yuan

Shanshan Weng

Affiliations

Soon will be listed here.

Citing Articles

The optimal time interval between neoadjuvant chemoradiotherapy and surgery for patients with an unfavorable pathological response in locally advanced rectal cancer: a retrospective cohort study.

Wang L, Fan J, Guo Y, Shang S, Gao H, Xu J Front Oncol. 2025; 15:1534148.

PMID: 40027126 PMC: 11867938. DOI: 10.3389/fonc.2025.1534148.

Lymph node yield does not affect the cancer-specific survival of patients with T1 colorectal cancer: a population-based retrospective study of the U.S. database and a Chinese registry.

Li J, Tian R, Huang F, Cheng P, Zhao F, Zhao Z Int J Colorectal Dis. 2025; 40(1):31.

PMID: 39909882 PMC: 11799036. DOI: 10.1007/s00384-025-04816-x.

References

Weng S, Yuan Y, Wang X, Chen G, Wang Y, Sheng W . Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019. Chin J Cancer Res. 2020; 32(3):403-407. PMC: 7369177. DOI: 10.21147/j.issn.1000-9604.2020.03.11. View

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

Andre T, Shiu K, Kim T, Jensen B, Jensen L, Punt C . Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020; 383(23):2207-2218. DOI: 10.1056/NEJMoa2017699. View

Ma X, Riaz N, Samstein R, Lee M, Makarov V, Valero C . Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity. Nat Genet. 2022; 54(7):996-1012. PMC: 10181095. DOI: 10.1038/s41588-022-01108-w. View

Wang F, He M, Yao Y, Zhao X, Wang Z, Jin Y . Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis. Cell Rep Med. 2021; 2(9):100383. PMC: 8484502. DOI: 10.1016/j.xcrm.2021.100383. View

Xu J, Kim T, Shen L, Sriuranpong V, Pan H, Xu R . Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study. J Clin Oncol. 2017; 36(4):350-358. DOI: 10.1200/JCO.2017.74.3245. View

Palles C, Cazier J, Howarth K, Domingo E, Jones A, Broderick P . Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet. 2012; 45(2):136-44. PMC: 3785128. DOI: 10.1038/ng.2503. View

Bond M, Bolhuis K, Loosveld O, de Groot J, Droogendijk H, Helgason H . First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group. Lancet Oncol. 2023; 24(7):757-771. DOI: 10.1016/S1470-2045(23)00219-X. View

Fakih M, Raghav K, Chang D, Larson T, Cohn A, Huyck T . Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study. EClinicalMedicine. 2023; 58:101917. PMC: 10119887. DOI: 10.1016/j.eclinm.2023.101917. View

10.

Yao J, Gong Y, Zhao W, Han Z, Guo S, Liu H . Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population. Sci Rep. 2019; 9(1):15767. PMC: 6823448. DOI: 10.1038/s41598-019-52414-z. View

11.

Wang F, Zhao Q, Wang Y, Jin Y, He M, Liu Z . Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncol. 2019; 5(10):1504-1506. PMC: 6696731. DOI: 10.1001/jamaoncol.2019.2963. View

12.

Hu H, Wang K, Huang M, Kang L, Wang W, Wang H . Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II Trial. Oncologist. 2021; 26(1):e90-e98. PMC: 7794191. DOI: 10.1634/theoncologist.2020-0563. View

13.

Forgo E, Gomez A, Steiner D, Zehnder J, Longacre T . Morphological, immunophenotypical and molecular features of hypermutation in colorectal carcinomas with mutations in DNA polymerase ε (POLE). Histopathology. 2019; 76(3):366-374. DOI: 10.1111/his.13984. View

14.

Yuan Y, Wang X, Chen G, Wang Y, Sheng W, Li X . Updates in version 2019 of CSCO guidelines for colorectal cancer from version 2018. Chin J Cancer Res. 2019; 31(3):423-425. PMC: 6613509. DOI: 10.21147/j.issn.1000-9604.2019.03.03. View

15.

Chalmers Z, Connelly C, Fabrizio D, Gay L, Ali S, Ennis R . Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017; 9(1):34. PMC: 5395719. DOI: 10.1186/s13073-017-0424-2. View

16.

Mi M, Weng S, Xu Z, Hu H, Wang Y, Yuan Y . CSCO guidelines for colorectal cancer version 2023: Updates and insights. Chin J Cancer Res. 2023; 35(3):233-238. PMC: 10334498. DOI: 10.21147/j.issn.1000-9604.2023.03.02. View

17.

Dong C, Ding Y, Weng S, Li G, Huang Y, Hu H . Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020. Chin J Cancer Res. 2021; 33(3):302-307. PMC: 8286893. DOI: 10.21147/j.issn.1000-9604.2021.03.02. View

18.

Prager G, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E . Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. N Engl J Med. 2023; 388(18):1657-1667. DOI: 10.1056/NEJMoa2214963. View

19.

Yuan Z, Weng S, Ye C, Hu H, Zhang S, Yuan Y . CSCO guidelines for colorectal cancer version 2022: Updates and discussions. Chin J Cancer Res. 2022; 34(2):67-70. PMC: 9086575. DOI: 10.21147/j.issn.1000-9604.2022.02.01. View

20.

Korona D, LeCompte K, Pursell Z . The high fidelity and unique error signature of human DNA polymerase epsilon. Nucleic Acids Res. 2010; 39(5):1763-73. PMC: 3061053. DOI: 10.1093/nar/gkq1034. View